Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer. However, stage IV ccRCC is generally incurable and its molecular mechanism has not yet been fully clarified. In this study, in order to screen differentially expressed genes (DEGs) between stage IV and stage I ccRCC specimens, we initially analyzed The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GSE73731). We found that maternal and embryonic leucine zipper kinase (MELK) is upregulated in stage IV ccRCC samples and that upregulation of MELK is significantly correlated with advanced disease status. Furthermore, both loss and gain-of-function assays strengthen the evidence that MELK enforces the malignant phenotype of ccRCC cells through overactivating the mammalian target of rapamycin complex 1 (mTORC1) pathway. Mechanistically, we verified that the oncogenic effect of MELK occurs through phosphorylating PRAS40, an inhibitory subunit of mTORC1, and through disrupting the interaction between PRAS40 and raptor. In summary, these results elucidate the important role of MELK in the progression of ccRCC and indicate that MELK may be a novel regulator of ccRCC progression by over-activating the mTORC1.
Introduction
Renal cell carcinoma (RCC) is the most fatal genitourinary malignancy and about 90% of renal tumors are clear cell renal cell carcinoma (ccRCC) 1 . Compared with stage I ccRCC, stage IV ccRCC is generally incurable and the survival time is shorter. It is thus necessary to study the mechanisms of stage IV ccRCC, and to identify highly specific progression-associated genes for finding new strategies for the treatment of advanced ccRCC. Previous studies have shown that ccRCC is characterized by von Hippel-Lindau (VHL) inactivation 2 , a governing event 3 inducing transcription of hypoxia-inducible factors (HIF) target genes, including VEGF, EPO, GLUT-1 and EGFR 4 , to accelerate ccRCC progression. Some studies have also reported that HIF-2 is implicated in angiogenesis and ccRCC metastasis 5, 6 , and obtaining PBRM1 or BAP1 mutation may set the process for ccRCC with different properties 7 . Metastatic ccRCC patients with truncated mutation of the PBRM1 gene gain more clinical benefits from immune checkpoint therapy 8 . Later research has validated that mutations in these genes were associated with advanced tumor stage 9 . Recently, Ho et al 10 . compared gene expression profiles between patientmatched primary and metastatic RCC tumors and found upregulation of ECM genes in metastases, including SLIT2, ADAMTS12, DCN, LUM, LAMA2, LMO3, and CECAM6. However, the mechanisms and core genes of advanced ccRCC need to be further studied and verified. Therefore, the aim of this research is to explore differentially expressed genes (DEGs) through comparing the gene expression profiles of stage I and stage IV ccRCC patients and verify the function and mechanisms of core genes via experiments. First, we conducted bioinformatics analysis for the DEGs and found that maternal embryonic leucine zipper kinase (MELK) is a seed gene in the network module. Then, we tested whether the MELK upregulation could accelerate ccRCC progression through a series of in vitro studies where we investigated the function of MELK in tumor cell proliferation, colony formation, migration, and invasion. Mechanistically, MELK could phosphorylate PRAS40 and over-activate mTORC1 by dissociating PRAS40 from raptor, and could subsequently promote the progression of ccRCC. Collectively, these results indicated that MELK may serve as a new therapeutic target in mTORC1 signalingactivated ccRCC cells.
Materials and Methods

Data Collection
The transcriptional data and clinical data of ccRCC are from TCGA (note 1) and GSE73731 (note 2). The RNA sequencing (RNA-seq) data from TCGA included 83 stage IV and 265 stage I ccRCC samples. The RNA-seq data from GSE73731 consisted of 44 stage IV and 41 stage I ccRCC specimens from patients.
Data Pre-processing and DEGs Screening
To screen DEGs, the linear models for microarray data (Limma) package from Bioconductor 11 were adopted to compare stage I and stage IV ccRCC samples from TCGA. Based on the Benjamini and Hochberg method, the associated p-values were adjusted to false discovery rates (FDRs). Q<0.05 and fold change >2 were selected as the cutoff criteria for screening of DEGs. We also used GEO2 R, a web tool applied to screen DEGs by comparing two groups of samples in a GEO series 12 , to identify the DEGs between stage I and stage IV ccRCC samples in GSE73731. The adjusted p-value <0.05 and fold change >1.5 were set as the thresholds for identifying DEGs. The online tool Venny2.1 was employed to compare the DEG sets from TCGA and GSE73731 as well as to identify the overlapped DEGs. The genes that appeared in both GSE73731 and TCGA were selected as the final DEGs.
GO and KEGG Pathway Enrichment Analysis of DEGs
Gene ontology (GO) enrichment analysis has been used as functional annotation of large-scale genes. The Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a comprehensive set of functional annotation 13, 14 . We carried out GO enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis in the DAVID database. The human genome was selected as the research background. A p-value <0.05 and count !5 were considered as having significant difference.
PPI Network Construction and Significant Module Extraction
The Search Tool for the Retrieval of Interacting Genes (STRING) database (note 3) offers both experimental and predictive interaction information. It is used for establishing a protein-protein interaction (PPI) network which can help understand the protein function and explain the relationship between proteins on a genome-wide scale 15 . The STRING 10.5 online tool was used to construct the PPI of the DEGs and Cytoscape plugin was used to create network visualization. Further, we analyzed the module of resulting PPI network with the Plugin Molecular Complex Detection (MCODE) with the parameters (node score cutoff !2, degree cutoff !2, K-core !2, and maximum depth ¼100) 16 . Finally, the seed gene could be identified.
Gene Set Enrichment Analysis
The patients with ccRCC were divided into two groups according to the expression of MELK (median MELK expression value was set as the cutoff). mTORC1 signaling gene set (HALLMARK_MOTRC1_SIGNALING) was obtained from the Molecular Signatures Database from the Broad Institute (note 4). We carried out gene set enrichment analysis by using the default settings, and permutations number was set at 1,000. A p-value <0.05 and FDR <0.25 were considered statistically significant.
Plasmid Construction
pCMV-MELK and pCMV control plasmids were purchased from BioVector (Beijing, China). The lentiviral system with MELK-inducible shRNA transfection starter kit was purchased from SunShineBio (Guangzhou Honsea Sunshine Bio-tech Co., Ltd, China). Catalog #RHS4696-200703132 and cat# RHS4696-200691582 were used for non-template control and shMELK. pENTER-Flag-PRAS40 was purchased from Vigene Biosciences (Shandong, China).
Cell Culture and Transfection
The cell lines ACHN and 769-P were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS, at 37 C and 5% CO 2 . Cells were transfected with lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) for plasmid transfection. MELK plasmid and control vector were transfected into 769-P and screened with G418 (700 mg/ml; Amresco, Solon, OH, USA). In addition, shMELK plasmid and shControl vector were transfected into ACHN cell and were screened by using 300 ng/ml puromycin (Sigma, St. Louis, MO, USA).
Cells were seeded in six-well plates (300 cells per well) and incubated for 10 days. Then, cells were stained with crystal violet and the colonies (>80 cells) were counted (BectonDickinson Biosciences, Bedford, MA, USA). Stable MELKtransfected 769-P, shMELK-1/2#-transfected ACHN, and control cells were cultured at a density of 5Â10 5 cells/well in a 6-well plate. The cell monolayer was scratched using a sterile 200 ml pipette tip across the center of the well. The areas of the wound were recorded at 0, 12, and 24 h after culture. Image J analysis software was used to measure the widths of three different wound surfaces within each group. The invasion assay was carried out using modified Boyden chambers coated with matrigel in 24-well plate (BectonDickinson Biosciences).
Coimmunoprecipitation
Lysates of 769-P cells transfected with vector, MELK, Flag-PRAS40, and ACHN cells transfected with shNC, shMELK, and Flag-PRAS40 were solubilized, clarified, and incubated with 3 ml anti-Flag antibodies with protein A/G-agarose for 3 h with end-over-end rotation at 4 C. After five washes in 1 ml ice-cold PBS buffer, the immunoprecipitated proteins were eluted from the beads with SDS-PAGE sample buffer.
Western Blot Analysis and Reagent
Cells were lysed in lysis buffer including 0.2% protease inhibitor cocktail III (Calbiochem, San Diego, CA; La Jolla, CA, USA). After homogenization, the cell lysates were incubated on ice for 30 min and centrifuged at 12,000 g for 10 min. The amount of total protein was measured by protein assay kit (Bio-Rad, Hercules, CA, USA), and the proteins were then mixed with SDS sample buffer and boiled for 5 min before loading into a 10% or 8% SDS-PAGE gel (BioRad, Hercules, CA, USA). The proteins were transferred onto nitrocellulose membrane after electrophoresis. The blots were blocked and then incubated with primary antibody followed by a horseradish peroxidase (HRP)-conjugated secondary antibody. Immunoreactive bands were visualized by enzyme-linked chemiluminescence with an ECL kit. The primary antibodies were as follows: anti-MELK (ab108529), anti-a-tubulin (ab7291), and antimTOR (ab2732) from Abcam (Cambridge, UK); anti-4E-BP1 (#9644), anti-p-4E-BP1 (T37/46) (#2855), anti-S6 (#2317), anti-p-S6 (S235/236) (#4858), anti-p-PRAS40 (Thr246) (#13175), anti-p-PRAS40 (Ser183) (#5936), and anti-raptor (#2280) from Cell Signaling Technology (Danvers, MA, USA); and anti-Flag from Sigma (#3165, St Louis, MO, USA). The immune complex was detected using HRPconjugated secondary antibodies (ZSGB-BIO, Beijing, China). Rapamycin was purchased from Sigma (Solon, OH, USA).
Statistical Analysis
Data were analyzed using SPSS 16.0 (IBM, Armonk, NY, USA) or GraphPad Prism 5 (GraphPad, CA, USA). Groups from TCGA were compared by using an unpaired, twotailed t-test or ANOVA and results were presented as mean + SD. Kaplan-Meier curves and log-rank test were used to analyze the overall survival and disease-free survival of patients with ccRCC. Results from cell culture were analyzed by using an unpaired, two-tailed t-test and results are presented as mean + SD. A p-value <0.05 was considered statistically significant and all experiments were repeated at least three times.
Results
Identification and Bioinformatics Analysis of the DEGs
To explore the DEGs between stage IV and stage I ccRCC, we first analyzed two independent RNA-seq data (TCGA, GSE73731). The preliminary analysis showed that a total of 1716 and 861 DEGs were extracted from TCGA and GSE73731 based on the R analysis and GEO2 (Fig. 1A ). There were 86 common DEGs in both datasets (Fig. 1B) , including 72 upregulated genes and 14 downregulated genes in stage IV ccRCC tissues compared with stage I ccRCC tissues. Then, GO enrichment and KEGG pathway analysis of DEGs with DAVID online suggested that the common DEGs were mainly enriched in biological processes related to mitotic nuclear division, cell division, G2/M transition mitotic cell, and cellular component associated with midbody, spindle, kinesin complex, and cell cycle pathway (Fig.  1C) . We further analyzed all common DEGs by using the STRING online database and Cytoscape software. A confidence score !0.7 was set as the cutoff criterion. The results showed that a total of 39 DEGs out of the 86 common DEGs were screened into the DEGs PPI network complex (Fig. 1D) . Finally, MELK was filtered out as the seed gene in the network (Fig. 1E) . These results suggested that MELK may play an important role in the progression of ccRCC.
Upregulation of MELK was Correlated with ccRCC Progression
In order to determine whether upregulation of MELK is correlated with disease progression, we analyzed the relationship between MELK expression and TNM stages of ccRCC patients in the TCGA database. The results suggested that MELK expression increased in patients with advanced ccRCC and was positively correlated with TNM stages (Fig. 2A) . We subsequently evaluated the prognostic significance of MELK in these ccRCC patients. As shown in Fig. 2B , ccRCC patients with higher MELK expression (the median MELK expression value was used as the cutoff for low and high expression) had lower overall survival and disease-free survival rates than those with lower MELK expression. Taken together, these findings indicated that upregulation of MELK may serve as an indicator in predicting poor prognosis of ccRCC and ccRCC progression.
Over-expression or Knock-down of MELK Promoted or Inhibited Proliferation, Invasion, and Colony Formation of ccRCC Cells
To investigate the role of MELK in ccRCC progression, we first determined the protein expression of MELK in ccRCC cell lines of ACHN and 769-P. As expected, MELK expression was relatively higher in ACHN cells isolated from metastatic foci than in 769-P cell lines isolated from primary foci (Fig. 3A) . Then, in order to conduct gain-offunction and loss-of-function analysis, 769-P cells were transfected with MELK over-expression plasmids, whereas ACHN cells were transfected with MELK shRNA plasmids. The successful over-expression and knock-down of MELK models were confirmed by western blot (Fig. 3A and Fig.  3B ). Subsequently, we employed these cell lines to perform biological function assays. The CCK-8 assay found that the over-expression of MELK in 769-P cells significantly increased the viability (Fig. 3C) , whereas knock-down of MELK in ACHN cells significantly reduced the viability (Fig. 3D) . The promotive or prohibitive effects of MELK on the proliferation of ccRCC cells were further confirmed by the plate colony formation assay. As shown in Fig. 3E , the number of colonies markedly increased in 769-P cells overexpressing MELK, compared with the control group. On the contrary, ACHN cells knocking-down MELK formed fewer colonies than shNC control cells (Fig. 3F) . Moreover, we verified the effect of MELK on the migration and invasive capacity of 769-P and ACHN cells. The wound healing and transwell assay results showed that MELK over-expression significantly enhanced the migration (Fig. 3G) and invasive (Fig. 3H ) potential of 769-P cells. Knock-down of MELK in ACHN cells significantly inhibited migration (Fig. 3I) and invasive (Fig. 3J ) capacity compared with shNC control cells. Consistent with these results, over-expression of MELK increased levels of cyclin D1, cyclin A, N-Cadherin, and Vimentin, and reduced levels of E-Cadherin compared with vector control cells (Fig. 3K) , whereas knock-down of MELK reduced levels of cyclin D1, cyclin A, N-Cadherin, and Vimentin, and increased levels of E-Cadherin compared with shNC control cells (Fig. 3L) . Added up, these findings suggested that MELK promoted the progression of ccRCC.
MELK Promoted the Progression of ccRCC by Activating mTORC1 Pathway
To investigate the effect of MELK on ccRCC progression, we conducted Gene Set Enrichment Analysis (GSEA) for MELK with higher and lower expression. The results showed that in both TCGA and GSE73731 databases (Fig.  4A) , the mTORC1 pathway was upregulated in the higher expression MELK group. Previous studies have reported that mTORC1 pathway plays an important role in the progression of various tumors. We thus hypothesized that MELK might promote ccRCC progression by activating the mTORC1 pathway. We first determined whether MELK could regulate the mTORC1 pathway by using western blot analysis. Results showed that over-expression of MELK in 769-P cells significantly activated the mTORC1 pathway as evaluated by its downstream signaling molecules, including S6K1 and 4E-BP1. In addition, the increase in the ratio of phosphorylated S6K1 to S6K1 further confirmed the activation of the mTORC1 pathway (Fig. 4B and Fig. 4C ). Conversely, knock-down of MELK in ACHN cells inhibited the activity of the mTORC1 pathway (Fig. 4D and Fig. 4E ). Given that MELK can promote the progression of ccRCC and activate the mTORC1 pathway, it is reasonable to assume that activation of the mTORC1 pathway mediates the function of MELK. As shown in Fig. 4F , the rise in P-S6K1 and P-4EBP1 and the increase in the ratio of P-S6K1 to S6K1 mediated by MELK were significantly eliminated when we blocked the mTORC1 pathway with 100 nM rapamycin, a specific mTOR inhibitor. Together, these results suggested that over-activation of the mTORC1 pathway was responsible for the MELK-mediated malignant phenotype of ccRCC cells.
MELK Involvement in mTROC1 Pathway by Phosphorylating PRAS40
Previous studies have found that proline-rich Akt substrate 40 (PRAS40) inhibits activation of the mTORC1 pathway and Akt-mediated phosphorylation of PRAS40 prevents its inhibition of mTORC1 17 . PRAS40 inhibits mTORC1 through competing with other substrates for raptor [17] [18] [19] . The dissociation of PRAS40 from raptor requires phosphorylation of PRAS40 at some sites 20 . Therefore, we examined whether MELK could regulate mTROC1 activation by phosphorylating PRAS40. We initially used western blot to evaluate levels of phosphorylating PRAS40, mTOR, and raptor in 769-P cells over-expressing MELK and ACHN cells knocking-down MELK. The results showed that overexpression of MELK in 769-P cells significantly increased p-PRAS40 (T246), whereas knock-down of MELK in ACHN cells had the opposite effect (Fig. 5A and Fig. 5B ). In addition, over-expressing or knock-down of MELK had no effect on levels of mTOR, raptor, and p-PRAS40 (S183). Then, to verify the interaction between PRAS40 and raptor in ccRCC cells, we transiently transfected Flag-PRAS40 into 769-P and ACHN cells and performed coimmunoprecipitation assays. As shown in Fig. 5C and Fig. 5D , raptor was pulled down by exogenous Flag-PRAS40, indicating that raptor and PRAS40 co-exist in a protein complex. Finally, we investigated whether the phosphorylation of PRAS40 (T246) by MELK is sufficient to release PRAS40 from raptor. We over-expressed Flag-PRAS40 in the constructed cell models and detected whether there existed changes in the interaction between raptor and PRAS40. Coimmunoprecipitation assays indicated that raptor increased in PRAS40 immunoprecipitates in knock-down of MELK ACHN cells (Fig. 5E) . Inversely, overexpression of MELK significantly inhibited the interaction between PRAS40 and raptor in 769-P cells (Fig. 5F ). Taken together, these findings suggested that MELK phosphorylates PRAS40 at T246 and enhances mTORC1 activity by dissociating PRAS40 from raptor.
Discussion
ccRCC is the most common type of renal cell carcinoma, and patients with advanced stage disease generally have poor prognosis. Elucidating the mechanism of ccRCC progression and finding new therapeutic targets have both theoretical and clinical implications. In our study, DEGs between stage IV and stage I ccRCC were initially screened by comparing the RNA-seq data from TCGA and GSE73731 databases. Next, GO enrichment and KEGG pathway analysis indicated that DEGs were enriched in mitotic division and cell cycle. Furthermore, MELK, the seed gene in the module, was screened out after PPI network construction and module analysis.
MELK is a member of the snf1/AMPK family of protein serine/threonine kinases 21, 22 which is critical for a range of biological functions, including mitotic progression, proliferation, apoptosis, and tumorigenesis [23] [24] [25] [26] . So far, significantly higher levels of MELK have been reported in human cancers of the breast, colon, pancreas, brain, and prostate compared with normal cells 27 . Moreover, previous studies have found the correlation between MELK expression and tumor progression for breast cancer and astrocytoma as well as prostate cancer [28] [29] [30] [31] . Overexpression of MELK has also been found to be correlated with poor survival in multiple cancer types [31] [32] [33] . Consistent with these findings, our results showed that MELK is upregulated in stage IV ccRCC tissues compared with stage I counterparts, and that over-expression of MELK is significantly correlated with both adverse clinicopathological characteristics and poor prognosis. Subsequently, to explore the function of MELK in ccRCC, we performed gain-of-function and loss-of-function analyses and found that MELK promotes ccRCC cell proliferation, colony formation, invasion, and migration. These findings suggested that MELK has a promotive effect in the progression of ccRCC.
Previous studies have reported that MELK may play a key role in tumor progression in various cancers through FOXM1 signaling 26 , eIF4B signaling 34 , and the NF-kB pathway 35 . Interestingly, using GSEA assay 36 , our signaling pathway screening showed that the mTORC1 pathway is enriched in the MELK higher expression group compared with the MELK lower counterparts. Given the importance of mTOR activation and targeting in poor prognosis ccRCC 37, 38 , we hypothesized that MELK might promote ccRCC progression by activating the mTORC1pathway. As expected, our results showed that MELK overexpression significantly activated the mTORC1 pathway, whereas knock-down of MELK did not. Moreover, inhibiting mTOR activity by rapamycin could significantly suppress mTORC1 activation in MELK-upregulated ccRCC cells. These findings indicated that MELK may act as an upstream molecule of mTOR and therefore has a regulatory effect. Further investigation showed that MELK promotes mTORC1 pathway activity through phosphorylating PRAS40, an inhibitory subunit of the mTORC1 pathway 39, 40 . Previous studies have suggested that PRAS40 inhibits mTORC1 activity through competing with substrates for raptor 19 . Phosphorylation of PRAS40 releases PRAS40 from mTORC1 allowing increased activity 41 , although there is little consensus about the phosphorylation sites. Rho et al. reported that phosphorylation at Thr246 is sufficient to release PRAS40 from mTORC1, both in vitro and in vivo 41, 42 . Wang et al. found that dissociation of PRAS40 from mTORC1 requires simultaneous phosphorylation of PRAS40 on T246 by Akt, and on S183 by mTOR itself 43, 44 . In our study, we observed that over-expression of MELK only increased the PRAS40 phosphorylation at Thr246, not at S183. Knock-down of MELK decreased the PRAS40 phosphorylation at Thr246 and had no effect on S183. More importantly, we confirmed that over-expression of MELKthat is, phosphorylating PRAS40 at Thr246-could disrupt the interaction between PRAS40 and raptor whereas knockdown of MELK could not.
Combining bioinformatics analysis and experiments, our research suggests that MELK may play a crucial role in the progression of ccRCC. Phosphorylation of PRAS40 at Thr246 by MELK dissociates PRAS40 from raptor and also augments mTORC1 pathway activity. Together, MELK represents a promising molecular and for future studies on mTORC1 signaling in ccRCC progression.
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